Compare ESQ & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | GERN |
|---|---|---|
| Founded | 2006 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 821.1M |
| IPO Year | 2017 | N/A |
| Metric | ESQ | GERN |
|---|---|---|
| Price | $111.89 | $1.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $120.33 | $2.17 |
| AVG Volume (30 Days) | 83.8K | ★ 14.2M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.15 | $26.91 |
| Revenue Next Year | $39.09 | $43.75 |
| P/E Ratio | $79.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $87.54 | $1.04 |
| 52 Week High | $119.86 | $2.01 |
| Indicator | ESQ | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 32.94 |
| Support Level | $103.31 | $1.24 |
| Resistance Level | $116.59 | $1.29 |
| Average True Range (ATR) | 2.64 | 0.09 |
| MACD | 0.72 | -0.02 |
| Stochastic Oscillator | 84.05 | 10.42 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.